According to the report, the Latin America RNA Analysis Market size is valued at USD 0.34 Billion in 2021 and is expected to grow at a CAGR of 12% to reach USD 0.59 Billion by 2026 during the forecast period 2021 to 2026.
The market is mainly driven by the increasing technological advancements, increasing investment in research and development by biotechnology and pharmaceutical companies, rising government and private funding, and growing preference for personalized medicines.
However, lack of skilled professionals in the transcriptomics field and lack of efficient bioinformatics and data analysis tools to analyse enormous data generated from the high-throughput sequencing technologies expected to restrain the growth of this market to a certain extent.
But still, in the forecast period, emerging economies like Latin America are anticipated to form new revenue-generating pockets for the market players. Economic developments and increasing government funding to support new product developments are the major factors fuelling the growth of the market in these regions.
This research report on the Latin America RNA Analysis Market has been segmented and sub-segmented into the following categories
By End User:
Noteworthy Companies dominating the Latin America RNA Analysis Market Profiled in the Report are Illumina Inc, Qiagen N.V, Affymetrix Inc, Agilent Technologies Inc, F. Hoffmann-La Roche Ltd, Sigma Aldrich, Fluidigm Corporation, Bio-Rad Laboratories Inc, GE Healthcare, and Thermofisher Scientific Inc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Academic Research & Government Institutes
5.1.3 Pharmaceutical & Biotechnology Companies
5.1.4 Hospitals & Diagnostic Centers
5.1.5 Y-o-Y Growth Analysis, By End User
5.1.6 Market Attractiveness Analysis, By End User
5.1.7 Market Share Analysis, By End User
5.2.3 Polymerase Chain Reaction (PCR)
5.2.4 Sequencing Technologies
184.108.40.206 Sanger Sequencing
220.127.116.11 Next Generation Sequencing (NGS)
5.2.5 RNAi Gene Silencing
5.2.6 Y-o-Y Growth Analysis, By Type
5.2.7 Market Attractiveness Analysis, By Type
5.2.8 Market Share Analysis, By Type
5.3.2 Clinical Diagnosis
5.3.3 Drug Discovery
5.3.5 Y-o-Y Growth Analysis, By Application
5.3.6 Market Attractiveness Analysis, By Application
5.3.7 Market Share Analysis, By Application
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By End User
126.96.36.199 By Type
188.8.131.52 By Application
6.1.4 Market Attractiveness Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By End User
18.104.22.168 By Type
22.214.171.124 By Application
6.1.5 Market Share Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By End User
184.108.40.206 By Type
220.127.116.11 By Application
6.5 Rest of Latin America
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Affymetrix Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Agilent Technologies, Inc.
8.3 Bio-Rad Laboratories, Inc.
8.4 GE Healthcare
8.5 Illumina, Inc.
8.6 Qiagen N.V.
8.7 F. Hoffmann-La Roche Ltd.
8.8 Sigma-Aldrich Corporation
8.9 Thermo Fisher Scientific, Inc.
8.10 Fluidigm Corporation
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures